XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities:    
Net loss $ (7,854,211) $ (8,299,479)
Adjustments to reconcile net loss to net cash used in operating activities    
Contingent consideration (1,299,000)
Depreciation 9,687 1,763
Share-based compensation expense 912,462 2,623,936
Finance lease amortization 127,617
Amortization of right-of-use assets 227,478 216,743
Changes in operating assets and liabilities    
Prepaid expenses (387,410) (699,253)
Accounts payable 707,314 284,132
Accrued liabilities (55,758) 351,453
Operating lease liabilities (214,431) (210,530)
Other changes in operating assets and liabilities (393) 108,850
Net cash used in operating activities (6,655,262) (6,793,768)
Cash flows from investing activities:    
Purchases of property, plant and equipment (1,445,174) (2,723)
Reimbursement of capital expenditures 994,410
Net cash used in investing activities (450,764) (2,723)
Cash flows from financing activities:    
PIPE proceeds 32,000,000
Cash received from Trust 19,031,516
Transaction expenses (10,043,793)
BCF Holdings capital repayment (3,750,000)
Repayments of notes payable - insurance premium financing (11,166)
Repayments of the principal portion of finance lease liabilities (44,469)
Warrant exercises 335,984
Deferred financing costs (22,570)
Net cash provided by financing activities 37,495,502
Net change in cash, cash equivalents and restricted cash (7,106,026) 30,699,011
Cash, cash equivalents and restricted cash, beginning of year 28,879,177 463,475
CENAQ operating cash balance acquired 91,454
Cash, cash equivalents and restricted cash, end of period 21,773,151 31,253,940
Supplemental cash flows:    
Non-cash income tax payable and deferred tax liability obtained from CENAQ 312,446
Non-cash impact of debt issuance through the business combination 409,612
Capital expenditures in accounts payable and accrued expenses (at period end) 469,244
Accounts receivable for reimbursement of capital expenditures (at period end) $ 223,818